Navigation Links
Anti-Cancer Drug CYT997 Update
Date:3/12/2008

MELBOURNE, Australia, March 12 /PRNewswire-FirstCall/ -- Cytopia Limited (ASX: CYT) has commenced dosing patients in the first of a suite of Phase II clinical studies for its vascular disrupting agent (VDA), CYT997. These studies will investigate the activity of this anti-cancer compound in specific cancer types with high unmet medical need and poor prognoses.

VDAs are a new class of drugs to treat cancer and have potential for "blockbuster" sales in the treatment of vascularized tumors. CYT997 has a dual mechanism of action shutting down established blood vessels that supply the tumor with nutrients and oxygen and also direct cytotoxic properties. Capable of being delivered orally as well as intravenously, the compound was discovered by Cytopia scientists in 2003 and an Investigational New Drug application was accepted by the US Food and Drug Administration in 2005 to commence Phase I studies.
During the 2008 financial year Cytopia has:

-- commenced dosing in its first Phase II study

-- finalized preparations for its second Phase II study

-- concluded its first Phase I safety and tolerability study with

intravenous administration

-- continued dose-escalation in its Phase I capsule dosing study (oral

administration)

Phase II clinical programs

1. Phase II trial in multiple myeloma Cytopia commenced dosing in its first Phase II efficacy study in patients with relapsed or refractory multiple myeloma in January 2008, some four months after conclusion of its initial Phase I study. The Phase II study is a two- stage design with an interim clinical activity analysis after 14 patients and maximum enrolment of 24 patients. Enrolment into this efficacy study is progressing on schedule and Cytopia anticipates undertaking interim data analysis by September this year.

This clinical study follows an extensive body of preclinical studies, including studies in cells from heavily pre-tr
'/>"/>

SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
2. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Aida Announces Completion of Anti-Cancer Drug Phase Two Testing
5. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
6. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
7. Treatment of First Patient in Phase I Clinical Trial of Bionomics Anti-Cancer Drug BNC105
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Texas , Nov. 21, 2014  World Hemp ... containing low THC, announces they are now offering legal, ... to Charlotte,s Web type strains grown in medical marijuana ... other neurological disorders, such as Parkinson,s, MS, and spinal ... US laws to pass, because imported CBD Oil Is ...
(Date:11/21/2014)... , 21. November 2014 /PRNewswire/ ... hat heute bekannt gegeben, dass die ... EMA) die Kennzeichnung als Orphan-Medizinprodukt an ... des Unternehmens zur Behandlung von Fibrodysplasia ... seltene, stark beeinträchtigende genetische Krankheit, die ...
(Date:11/21/2014)... Nov. 20, 2014  Market research firm Kalorama information says ... The Buy, in the medical device industry.  The firm ... will produce just 3% growth this year, which led ... of product lines and entrance by acquisition into new ... medical devices, The Global Market for Medical Devices, ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2
... HONG KONG, Feb. 25, 2011 /PRNewswire-Asia-FirstCall/ -- Golden ... - 801.HK; 910801.TW), China,s leading integrated healthcare enterprise, ... acquire the remaining interests in the Group,s Chinese ... HK$90 million in shares.  Upon completion of the ...
... Calif., Feb. 24, 2011 Amgen (Nasdaq: AMGN ... 3 head-to-head trial that compared XGEVA ™ (denosumab) to ... skeletal-related events (SREs) in 1,901 men with prostate cancer and ... met its primary and secondary endpoints and demonstrated XGEVA,s superiority ...
Cached Medicine Technology:Golden Meditech Acquires Remaining Stake in Chinese Herbal Medicine Business 2Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 2Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 3Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 4Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 5Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 6Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 7Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 8Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 9
(Date:11/22/2014)... NC (PRWEB) November 23, 2014 Cancer ... found a connection between intercellular communication tunnels and the ... read the full story on the Surviving Mesothelioma ... Center and the University of Minnesota have just released ... carry information and materials between cells. They found that ...
(Date:11/22/2014)... A classic black prom dress will never go ... suppliers, has unveiled its new items of black prom ... at a big discount, up to 70% off. People throughout ... new black prom dresses, made with the best materials, can ... of all customers, the company provides these beautiful outfits in ...
(Date:11/22/2014)... Today, Dylan Queen, a renowned brand in wedding ... the business offers a wide range of special occasion ... allowing them to create multiple looks easily. , According ... collection of chic wedding dresses has been prepared for ... discounted rates now. Dylan Queen can always create what ...
(Date:11/22/2014)... Discount-Dress.com is an important company in the dress industry. ... company’s online market share by a series of promotions. Recently, ... announced a bridesmaid dress promotion for the new year 2015. ... the dresses from this company are not only of high ... very good at manufacturing wedding dresses. Customers prefer to choose ...
(Date:11/22/2014)... "My friend went in for a mammogram ... said an inventor from Cambria Heights, N.Y. "To add ... second time because the first results were inaccurate. Her ... patent-pending MAMO EASY to offer a more comfortable way ... patient from the pain normally involved with this procedure. ...
Breaking Medicine News(10 mins):Health News:Study Links Cellular ‘Tunnels’ to Mesothelioma Proliferation, According to Surviving Mesothelioma 2Health News:New Black Prom Dresses from BellasDress.com 2Health News:Dylan Queen Introduces Its New Wedding Dresses 2Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2
... ... company, now offers their clients a choice between a Flat Fee Plan and a Monthly ... Miami, FL ... cash strapped plaintiffs don’t have to wait for their lawsuits to recover, they can get ...
... NASHVILLE, Tenn., Dec. 10 Pathological gambling can be ... inhibitions, according to researchers at the annual meeting of ... outcomes in gamblers treated with medications often used for ... his team at the University of Minnesota used tasks ...
... The 2009 American College of Neuropsychopharmacology Annual Meeting ... schizophrenia and treatment for gambling addiction. Study highlights ... Techniques to Assess PTSD. Working with Iraq and ... may be useful to evaluate PTSD and develop ...
... ... a leading neurologist, Dr. Alexander Mauskop, renowned headache expert and founder of the New ... ... 9, 2009 -- A powerful headache medicine developed by a leading neurologist for his ...
... , WARRINGTON, Pa., Dec. 9 Last year Special Equestrians was ... part of $25,000 in PR service grants. "We,ve always taken corporate ... a warm and fuzzy feeling to do what little we can ... co-founder, Christopher L. Simmons. "We learned many years ago that it ...
... Award Will Create New Construction and Permanent Jobs in the South ... Additional 12,000 Residents , NEW YORK, Dec. 9 ... Reinvestment Act (Recovery Act) grant to support a new addition to ... announced by President Barack Obama as part of his plan to ...
Cached Medicine News:Health News:Injury Funds Now To the Rescue with New Lawsuit Funding Service 2Health News:Pathological Gambling May Be Successfully Treated With Medications for Substance Addiction 2Health News:Late-breaking brain and behavior research presented at ACNP annual meeting this week 2Health News:Breakthrough Approach to Age-old Ailment, Renowned Doctor Introduces Powerful Headache Medicine 2Health News:Breakthrough Approach to Age-old Ailment, Renowned Doctor Introduces Powerful Headache Medicine 3Health News:Nonprofit Partners With PR Company and Gains International Attention 2Health News:$12 Million American Recovery and Reinvestment Act Grant Awarded to Urban Health Plan, Inc. (UHP) 2Health News:$12 Million American Recovery and Reinvestment Act Grant Awarded to Urban Health Plan, Inc. (UHP) 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: